Bernstein Initiates Coverage on Alexion Pharmaceuticals (ALXN) with at Market Perform
More News related to ALXN
- Alexion to Present at Lazard Capital Markets 6th Annual Healthcare Conference
- Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of Patients With PNH at the ASH Annual Meeting
- Bernstein Initiates Coverage on Alexion Pharmaceuticals (ALXN) with at Market Perform
- Alexion to Present at Credit Suisse's 2009 Healthcare Conference
- Bank of America Initiates Coverage on Alexion Pharmaceuticals (ALXN) with a Neutral
More News related to New Coverage
- Wedbush Starts Omeros (OMER) at Outperform with a $12 Fair Value
- Davenport Starts C&F Financial (CFFI) at Buy, $23.50 Price Target
- JANCO Partners Initiates Coverage on IMAX Corp (IMAX) with a Buy; Upside Margin Leverage, Studios/Exhibitors Win
- Barclays Initiates Coverage on AGCO Corporation (AGCO) with an Equalweight
- Wunderlich Securities Initiates Coverage on EXCO Resources (XCO) with a Buy
Bernstein initiates coverage on Alexion Pharmaceuticals (Nasdaq: ALXN) with at Market Perform. Price target $49.
To see more analyst ratings on ALXN Click Here.
Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company engaged in the discovery, development and delivery of biologic therapeutic products for the treatment disease, including hematologic and neurologic diseases, cancer and autoimmune disorders.
Related Categories
New CoverageStocks Mentioned
-0.46Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
